Portal de Periódicos da CAPES

Effects of neoadjuvant chemotherapy on respiratory function in patients with breast cancer

2020; AME Publishing Company; Volume: 32; Issue: 1 Linguagem: Inglês

10.21147/j.issn.1000-9604.2020.01.05

1993-0631

Lei Ding, Liping Wang, Jian Yin, Zhiyi Fan, Zi-jing He,

Childhood Cancer Survivors' Quality of Life

To evaluate changes in chest X-rays, pulmonary function tests (PFTs) and quality of life in female breast cancer patients who had been treated with four cycles of neoadjuvant chemotherapy consisting of a regimen of cyclophosphamide, epirubicin and 5-fluorouracil (CEF regimen), and to determine the correlation between pulmonary function parameters and declined quality of life.Twenty-nine eligible female patients diagnosed with breast cancer at the first visit who were 20-60 years old, were classified as the American Society of Anesthesiologists (ASA) I-II and patients whose body mass index (BMI) <30 kg/m2 were recruited and subjected to chest X-ray examinations, PFTs and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) questionnaire before and after receiving 4 cycles of the CEF regimen.In this study, chest X-rays showed no abnormal changes after chemotherapy, but significant decreases in carbon monoxide diffusing capacity (DLCO) and percentage of the DLCO predicted value (DLCO%) (P<0.001). A significant increase in maximal ventilatory volume (MVV) (P=0.004) was observed, and most patients experienced dyspnea (P=0.031) and fatigue (P 0.05).Neoadjuvant chemotherapy can reduce lung diffusion function and quality of life in females with breast cancer.